Goldman Sachs analyst Kash Rangan maintains Zoom Video Comms (NASDAQ:ZM) with a Neutral and lowers the price target from $104 to $90.
Benchmark Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $636
Benchmark analyst Aydin Huseynov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $590 to $636.